Patent US3340881A successfully refreshed from Google Patents.
US5630842A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Biocompatible surgical implant
Assignee: Angiotech Pharmaceuticals Inc
•
Filing: 1994-01-26
•
Granted: 1997-05-20
•
Expires: 2014-01-26
Abstract
Abstract The invention provides a biocompatible surgical implant particularly useful for breast or testicular reconstruction or augmentation comprising a stabilized fibrin semisolid, optionally sealed in a shaped shell. Preferred starting material for production of the implant is whole plasma from autologous or homologous donation, concentrated with respect to fibrinogen.
Inventors
- 👤 Teresa Brodniewicz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 04:53
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/14; A61L27/22; A61L27/225; A61F; A61F2/00; A61F2/02; A61F2/12; A61L27/36; A61F2310/00; A61F2310/00005; A61F2310/00365; A61F2310/00377
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
67 words
A surgical prosthesis for soft tissue reconstruction or augmentation in a mammal comprising a resorption-resistant semisolid fibrin coagulate consisting essentially of insoluble fibrin polymer strands stabilized against biodegradation and sealed in a biocompatible, resorption-resistant plastic shell, wherein the semisolid fibrin coagulate is produced from a fibrinogen solution consisting essentially of fibrinogen, thrombin, and factor XIII in amounts sufficient to substantially convert the fibrinogen to insoluble fibrin polymer.
Claim 2
Dependent Claim
67 words
A surgical prosthesis for soft tissue reconstruction or augmentation in a mammal comprising a resorption-resistant semisolid fibrin coagulate consisting essentially of insoluble fibrin polymer strands stabilized against biodegradation and sealed in a biocompatible, resorption-resistant plastic shell, wherein the semisolid fibrin coagulate is produced from a fibrinogen solution consisting essentially of fibrinogen, thrombin, and factor XIII in amounts sufficient to substantially convert the fibrinogen to insoluble fibrin polymer.
Claim 3
Dependent Claim
36 words
The prosthesis of claim 1, wherein the semisolid fibrin coagulate is produced from a plasma fraction consisting essentially of fibrinogen, thrombin, and factor XIII in amounts sufficient to substantially convert the fibrinogen to insoluble fibrin polymer.
Claim 4
Dependent Claim
14 words
The prosthesis of claim 1, wherein the fibrinogen solution further includes a cocrosslinking agent.
Claim 5
Dependent Claim
15 words
The surgical prosthesis of claim 2, wherein the plasma fraction further includes a cocrosslinking agent.
Claim 6
Dependent Claim
38 words
The surgical prosthesis of claim 1, wherein the fibrinogen solution contains from about 1 to 1000 IU thrombin per about 2 to 150 mg fibrinogen, and about 0.01 to 250 units factor XIII per about 1 gm fibrinogen.
Claim 7
Dependent Claim
38 words
The surgical prosthesis of claim 2, wherein the plasma fraction contains from about 1 to 1000 IU thrombin per about 2 to 150 mg fibrinogen, and about 0.01 to 250 units factor XIII per about 1 gm fibrinogen.
Claim 8
Dependent Claim
28 words
The surgical prosthesis of claim 3, wherein the cocrosslinking agent is calcium chloride present in the fibrinogen solution in a concentration of about 0.001 to about 50 mM.
Claim 9
Dependent Claim
28 words
The surgical prosthesis of claim 4, wherein the cocrosslinking agent is calcium chloride present in the plasma fraction in a concentration of about 0.001 to about 50 mM.
Claim 10
Dependent Claim
18 words
The surgical prosthesis of claim 4, wherein the plasma fraction is substantially free of biologically active proteolytic enzymes.
Claim 11
Dependent Claim
17 words
The surgical prosthesis of claim 9, wherein the coagulate is stabilized by treatment with a crosslinking agent.
Claim 12
Dependent Claim
37 words
The surgical prosthesis of claim 2, stabilized against biodegradation by substantial removal of plasma components deleterious to the stability of the product from the plasma fraction; deactivation of proteolytic enzymes present; and crosslinkage of the fibrin polymer.
Claim 13
Dependent Claim
16 words
The surgical prosthesis of claim 2, wherein the plasma is autologous or homologous to the mammal.
Claim 14
Dependent Claim
16 words
The surgical prosthesis of claim 6, wherein the plasma is autologous or homologous to the mammal.
Claim 15
Dependent Claim
15 words
The surgical prosthesis of claim 1, wherein the prosthesis is a breast or testicle prosthesis.
Claim 16
Dependent Claim
15 words
The surgical prosthesis of claim 2, wherein the prosthesis is a breast or testicle prosthesis.
Claim 17
Dependent Claim
22 words
The surgical prosthesis of claim 2, wherein the prosthesis is a breast prosthesis and wherein the plasma is autologous to the mammal.
Claim 18
Dependent Claim
13 words
The prosthesis of claim 1, implanted in the soft tissue of a mammal.
Claim 19
Dependent Claim
20 words
A method for soft tissue anaplasty in a mammal comprising surgically implanting the prosthesis of claim 1 in the mammal.
Claim 20
Dependent Claim
20 words
A method for soft tissue anaplasty in a mammal comprising surgically implanting the prosthesis of claim 2 in the mammal.
Claim 21
Dependent Claim
20 words
A method for soft tissue anaplasty in a mammal, comprising surgically implanting the prosthesis of claim 15 in the mammal.
Claim 22
Dependent Claim
21 words
A method for mammaplasty in a mammal, comprising surgically implanting the prosthesis of claim 16 in the breast of the mammal.
Claim 23
Dependent Claim
18 words
The surgical prosthesis of claim 1, having a deformability corresponding to a Precision Penetrometer reading of about 180.
Claim 24
Dependent Claim
18 words
The surgical prosthesis of claim 2, having a deformability corresponding to a Precision Penetrometer reading of about 180.
References Cited (Backward Citations)
US2576006A
Cited
US3933996A
Cited
US4157085A
Cited
US4507810A
Cited
US4647536A
Cited
US4960757A
Cited
EP0166263A1
Cited
US4648880A
Cited
US4822535A
Cited
US4863733A
Cited
US4925678A
Cited
US5002071A
Cited
EP0305243A1
Cited
US5112457A
Cited
EP0485210A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-05-19 | 2000-11-18 | 2001-05-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-05-19 | 2004-11-18 | 2005-05-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-05-19 | 2008-11-18 | 2009-05-20 | $7700.00 | Window Closed / Lapsed |